Biotech Values

[walldiver]

DNDN -- The expansion of 9902B into Europe is a BSR idea...I think a lot could be accomplished by opening up more Canadian sites (currently only one or two Ontario sites are open), expanding into Australia, and perhaps one or two NW European countries such as Germany and the UK. The UK because of a high incidence of PC plus no language barrier, and Germany because that country seems to be fairly enthusiastic about cancer vaccines (Merck KGaA). Increase the 9902B trial size to 600 patients, halt US enrollment, and start an expanded access program for minority patients (especially African Americans), who disproportionately suffer from AIPC but were under-represented in the Provenge trials.